Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

Expanding Access to High-Quality Healthcare

Dr. Jason Cross, Co-founder & Chief Strategy Officer at Rymedi, dives into Connected Health, including how it can be used to expand access to high-quality healthcare, current barriers to its...

Impetus Digital

- PMLiVE

FDA places partial clinical hold on three Gilead phase 3 trials for MDS and AML treatments

The company confirmed that six other phase 2 trials would go ahead as previously planned

- PMLiVE

Janssen’s Tremfya receives positive results for active psoriatic arthritis

The drug demonstrated positive joint efficacy and ranked highest for skin clearance when compared to existing therapies

- PMLiVE

ARISE – a strategic healthcare communication planning process from Bedrock

Bedrock Healthcare Communications MD Marie Little talks through the ARISE process and the clarity it brings to clients.

Bedrock Healthcare Communications

- PMLiVE

Pfizer and BioNTech start clinical trial for Omicron-based COVID-19 vaccine

The clinical trial involves adults aged 18 to 55 who received an Omicron-based vaccine candidate as part of a two-dose primary series, as well as a booster

- PMLiVE

FDA restricts use of certain antibody treatments for COVID-19

The restrictions reflect recent data that shows these antibodies are not effective against the Omicron variant

https://youtu.be/_T3WV2TR0U8

Let’s explore new frontiers

Oxford PharmaGenesis

- PMLiVE

FDA grants priority review for Roche’s Evrysdi for spinal muscular atrophy in babies

The review of Evrysdi has been developed for pre-symptomatic babies under two months old with spinal muscular atrophy

- PMLiVE

Ipsen’s Sohonos approved by Health Canada

The drug is the first approved treatment for individuals with fibrodysplasia ossificans progressiva

- PMLiVE

Personalised medicine: driving a need for greater diversity in clinical trials

Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today.

Innovative Trials

Lucid Group Welcomes a New Cohort of Graduates into its Futures Academy

We are excited to welcome this year’s cohort of graduates into our Lucid Futures Academy, which is now into its sixth year after being launched in Oct 2017.The Futures Academy...

Lucid Group Communications Limited

- PMLiVE

Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19

The FDA also issued an EUA for the treatment to include non-hospitalised paediatric patients 12 years and under who are at high risk of disease progression

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links